Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kerenaftali Klein

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|January 25, 2012
Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug-drug interaction studies for CYP2C9Kerenaftali Klein, Ivelina Gueorguieva, Leon Aarons
Plos One|April 13, 2016
A Bayesian Modelling Approach with Balancing Informative Prior for Analysing Imbalanced DataKerenaftali Klein, Stefanie Hennig, Sanjoy Ketan Paul
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|August 28, 2012
Gait speed as a measure in geriatric assessment in clinical settings: a systematic reviewNancye M Peel, Suzanne S Kuys, Kerenaftali Klein
Paediatric Respiratory Reviews|June 5, 2016
A systematic review of studies examining the rate of lung function decline in patients with cystic fibrosisSabariah Noor Harun, Claire Wainwright, Kerenaftali Klein, et al.
Journal of Diabetes|May 2, 2015
Association of smoking and concomitant metformin use with cardiovascular events and mortality in people newly diagnosed with type 2 diabetesSanjoy K Paul, Kerenaftali Klein, Azeem Majeed, et al.
Journal of Diabetes|August 30, 2014
Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weeklySanjoy K Paul, David Maggs, Kerenaftali Klein, et al.
Cardiovascular Diabetology|January 25, 2015
The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational studySanjoy K Paul, Kerenaftali Klein, David Maggs, et al.
International Journal of Nephrology|January 15, 2013
Pre-, pro-, and synbiotics: do they have a role in reducing uremic toxins? A systematic review and meta-analysisMegan Rossi, Kerenaftali Klein, David W Johnson, et al.
Diseases of the Colon and Rectum|August 11, 2017
Measurement Bias of Polyp Size at ColonoscopyShinichiro Sakata, Kerenaftali Klein, Andrew R L Stevenson, et al.
Plastic and Reconstructive Surgery|September 6, 2013
Factors affecting return to work following facial traumaScott C Borgna, Kerenaftali Klein, Laurence E Harvey, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Journal of Pharmacokinetics and Pharmacodynamics|January 25, 2012
Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug-drug interaction studies for CYP2C9Kerenaftali Klein, Ivelina Gueorguieva, Leon Aarons
Plos One|April 13, 2016
A Bayesian Modelling Approach with Balancing Informative Prior for Analysing Imbalanced DataKerenaftali Klein, Stefanie Hennig, Sanjoy Ketan Paul
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|August 28, 2012
Gait speed as a measure in geriatric assessment in clinical settings: a systematic reviewNancye M Peel, Suzanne S Kuys, Kerenaftali Klein
Paediatric Respiratory Reviews|June 5, 2016
A systematic review of studies examining the rate of lung function decline in patients with cystic fibrosisSabariah Noor Harun, Claire Wainwright, Kerenaftali Klein, et al.
Journal of Diabetes|May 2, 2015
Association of smoking and concomitant metformin use with cardiovascular events and mortality in people newly diagnosed with type 2 diabetesSanjoy K Paul, Kerenaftali Klein, Azeem Majeed, et al.
Journal of Diabetes|August 30, 2014
Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weeklySanjoy K Paul, David Maggs, Kerenaftali Klein, et al.
Cardiovascular Diabetology|January 25, 2015
The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational studySanjoy K Paul, Kerenaftali Klein, David Maggs, et al.
International Journal of Nephrology|January 15, 2013
Pre-, pro-, and synbiotics: do they have a role in reducing uremic toxins? A systematic review and meta-analysisMegan Rossi, Kerenaftali Klein, David W Johnson, et al.
Diseases of the Colon and Rectum|August 11, 2017
Measurement Bias of Polyp Size at ColonoscopyShinichiro Sakata, Kerenaftali Klein, Andrew R L Stevenson, et al.
Plastic and Reconstructive Surgery|September 6, 2013
Factors affecting return to work following facial traumaScott C Borgna, Kerenaftali Klein, Laurence E Harvey, et al.
Pageof 4